PT1689360T - Formulações de pó seco - Google Patents

Formulações de pó seco

Info

Publication number: PT1689360T
Authority: PT; Portugal
Prior art keywords: dry powder; powder formulations; formulations; dry; powder
Prior art date: 2003-11-14

Application number

PT47989272T

Other languages

English (en)

Inventor

Mueller-Walz Rudi

Steiner Roland

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-14

Filing date

2004-11-04

Publication date

2017-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1689360(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-04 Application filed by Jagotec Ag filed Critical Jagotec Ag

2017-09-22 Publication of PT1689360T publication Critical patent/PT1689360T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Seasonings (AREA)
Manufacturing Of Micro-Capsules (AREA)

PT47989272T 2003-11-14 2004-11-04 Formulações de pó seco PT1689360T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0326632.7A GB0326632D0 (en)	2003-11-14	2003-11-14	Dry powder formulations

Publications (1)

Publication Number	Publication Date
PT1689360T true PT1689360T (pt)	2017-09-22

Family

ID=29726600

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT47989272T PT1689360T (pt)	2003-11-14	2004-11-04	Formulações de pó seco
PT181577412T PT3354263T (pt)	2003-11-14	2004-11-04	Formulações de pó seco

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT181577412T PT3354263T (pt)	2003-11-14	2004-11-04	Formulações de pó seco

Country Status (17)

Country	Link
US (5)	US20070071690A1 (pt)
EP (3)	EP1689360B1 (pt)
JP (1)	JP4991304B2 (pt)
CN (2)	CN1878537B (pt)
AU (1)	AU2004288644B2 (pt)
CA (1)	CA2542450C (pt)
CY (1)	CY1119350T1 (pt)
DK (2)	DK1689360T3 (pt)
ES (2)	ES2645442T3 (pt)
FI (1)	FI3354263T3 (pt)
GB (1)	GB0326632D0 (pt)
HK (1)	HK1201447A1 (pt)
HU (2)	HUE034450T2 (pt)
PL (2)	PL3354263T3 (pt)
PT (2)	PT1689360T (pt)
SI (2)	SI1689360T1 (pt)
WO (1)	WO2005046636A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
GB0525254D0 (en) *	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
AU2012200449B2 (en) *	2005-12-21	2013-07-25	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7737145B2 (en)	2005-12-29	2010-06-15	Estrellita Pharmaceuticals, Llc	Diamine derivatives as inhibitors of leukotriene A4 hydrolase
WO2007077135A1 (en) *	2005-12-30	2007-07-12	Krka, Tovarna Zdravil, D.D., Novo Mesto	Pharmaceutical composition containing montelukast
EP1803457A1 (en) *	2005-12-30	2007-07-04	Krka Tovarna Zdravil, D.D., Novo Mesto	Pharmaceutical composition containing montelukast
GB0602897D0 (en) *	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
GB0613161D0 (en)	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
GB0625303D0 (en) *	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
HUE067290T2 (hu)	2009-02-26	2024-10-28	Glaxo Group Ltd	4-{(1 R)-2-[(6-{2-[(2,6-diklórbenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroxi-metil)fenolt tartalmazó gyógyszerkészítmények
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
MX336414B (es) *	2010-04-01	2016-01-19	Chiesi Farma Spa	Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
GEP20156343B (en) *	2010-08-03	2015-08-10	Chiesi Farma Spa	Dry powder formulation comprising a phosphodiesterase inhibitor
MX2013001936A (es) *	2010-08-23	2013-03-08	Takeda Gmbh	Particulas humidificadas que comprenden una sustancia terapeuticamente activa.
US9642798B2 (en)	2010-09-29	2017-05-09	Pulmatrix, Inc.	Monovalent metal cation dry powders for inhalation
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JO3510B1 (ar)	2011-03-04	2020-07-05	Heptares Therapeutics Ltd	استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US10130800B2 (en)	2012-01-27	2018-11-20	Invisiderm, Llc	Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
HK1204989A1 (en) *	2012-02-29	2015-12-11	Pulmatrix Operating Company, Inc.	Inhalable dry powders
CN104302650B (zh)	2012-03-13	2017-07-18	瑞斯比维特有限公司	晶体pi3激酶抑制剂
CA2869849A1 (en)	2012-04-13	2013-10-17	Glaxosmithkline Intellectual Property Development Limited	Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
KR20130140358A (ko)	2012-06-14	2013-12-24	한미약품 주식회사	살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
GB201222679D0 (en)	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
RU2686101C2 (ru)	2013-03-12	2019-04-24	Селтакссис, Инк.	Способы ингибирования лейкотриен- а4-гидролазы
WO2014152229A2 (en)	2013-03-14	2014-09-25	Celtaxsys, Inc.	Inhibitors of leukotriene a4 hydrolase
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
HK1223541A1 (zh) *	2013-10-22	2017-08-04	The General Hospital Corporation	色甘酸衍生物以及成像和治疗的相关方法
WO2015089105A1 (en)	2013-12-09	2015-06-18	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
CN105412049B (zh) *	2014-09-16	2020-01-07	四川海思科制药有限公司	一种干粉吸入剂用药物组合物及其制备方法
CN107106641B (zh)	2014-10-31	2021-12-21	葛兰素史密斯克莱知识产权发展有限公司	粉末制剂
EP3242676B1 (en)	2015-01-07	2023-10-04	Tonix Pharmaceuticals Holding Corp.	Magnesium-containing oxytocin formulations and methods of use
CN207896252U (zh) *	2015-09-25	2018-09-21	株式会社村田制作所	天线模块以及电子设备
DK3442560T3 (da)	2016-04-12	2025-02-24	Tonix Pharma Ltd	Magnesium-indeholdende oxytocinformuleringer og fremgangsmåder til anvendelse
TWI745396B (zh)	2016-07-12	2021-11-11	日商鹽野義製藥股份有限公司	吸入用醫藥組成物
KR20190044647A (ko)	2016-08-31	2019-04-30	더 제너럴 하스피탈 코포레이션	신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
MX2020010928A (es)	2018-04-16	2020-11-06	Ioulia Tseti	Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
WO2019232306A1 (en)	2018-05-31	2019-12-05	Celtaxsys, Inc.	Method of reducing pulmonary exacerbations in respiratory disease patients
CN110856713B (zh) *	2018-08-23	2021-08-24	山东大学齐鲁医院	一种便携式治疗急性心衰发作的吸入式药物
US10966943B2 (en)	2018-09-06	2021-04-06	Innopharmascreen Inc.	Methods and compositions for treatment of asthma or parkinson's disease
US12383528B2 (en)	2018-12-10	2025-08-12	The General Hospital Corporation	Cromolyn esters and uses thereof
CN109745565B (zh) *	2019-01-28	2021-05-18	上海方予健康医药科技有限公司	一种用于吸入的干粉组合物及其制备方法
JP2023520580A (ja)	2020-04-06	2023-05-17	ザジェネラルホスピタルコーポレイション	コロナウイルス誘発炎症状態の処置方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US175214A (en) *		1876-03-21		Elastic fluid turbine
DD98022A1 (pt)	1972-06-30	1973-06-12
JPS528375B2 (pt)	1973-07-02	1977-03-09
AT347054B (de)	1973-09-29	1978-12-11	Takeda Chemical Industries Ltd	Verfahren zur herstellung von neuen nonapeptidamid-derivaten
BE847762A (fr)	1975-10-29	1977-02-14		Nouveaux nonapeptides et procedes pour les preparer,
JPS5944308B2 (ja)	1976-03-23	1984-10-29	武田薬品工業株式会社	ペプタイド
US4124577A (en)	1977-06-13	1978-11-07	Warner-Lambert	Nonapeptides and methods for their production
US4317815A (en)	1979-06-13	1982-03-02	Coy David Howard	LH-RH Antagonists
US4672108A (en)	1981-12-07	1987-06-09	Hoffmann-La Roche Inc.	Crystalline human leukocyte interferon
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB8622090D0 (en)	1986-09-12	1986-10-22	Wellcome Found	Pharmacologically active compounds
US5110904A (en)	1989-08-07	1992-05-05	Abbott Laboratories	Lhrh analogs
JP2861267B2 (ja)	1989-06-01	1999-02-24	萬有製薬株式会社	生理活性物質ｂｅ―１８２５７類
GB8919726D0 (en)	1989-08-31	1989-10-11	Fujisawa Pharmaceutical Co	Ws7338 substances and preparation thereof
CA2032559C (en)	1989-12-28	2001-11-06	Kiyofumi Ishikawa	Endothelin antagonistic cyclic pentapeptides
US5284828A (en)	1990-05-14	1994-02-08	Fujisawa Pharmaceutical Co. Ltd.	Peptide compound and its preparation
CA2059380A1 (en)	1991-01-24	1992-07-25	Yiu-Kuen T. Lam	Endothelin receptor antagonists isolated from microbispora
US5874063A (en)	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
ES2103857T3 (es)	1991-08-13	1997-10-01	Takeda Chemical Industries Ltd	Peptidos ciclicos y su uso.
US5981719A (en)	1993-03-09	1999-11-09	Epic Therapeutics, Inc.	Macromolecular microparticles and methods of production and use
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
JP3628333B2 (ja)	1995-09-21	2005-03-09	ジェネンテックインコーポレーテッド	ヒト成長ホルモン変異体
DE59605366D1 (de)	1995-12-07	2000-07-06	Jago Pharma Ag Muttenz	Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers
NL1006774C2 (nl) *	1996-08-14	1998-09-28	Univ Potchefstroom	Anti-atherosclerose- en anti-trombotisch middel en het gebruik daarvan.
GB9806462D0 (en)	1998-03-26	1998-05-27	Glaxo Group Ltd	Improved compositions for inhalation
DE59914603D1 (de) *	1998-11-13	2008-02-14	Jagotec Ag	Multidosis-Trockenpulverinhalator mit Pulverreservoir
US20070212422A1 (en)	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
HUP0200185A3 (en)	1999-03-05	2006-07-28	Chiesi Farma Spa	Improved powdery pharmaceutical compositions for inhalation
EP1129705A1 (en)	2000-02-17	2001-09-05	Rijksuniversiteit te Groningen	Powder formulation for inhalation
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
WO2002007705A1 (en)	2000-07-20	2002-01-31	Campina B.V.	Carrier material for dry powder inhalation
JP4125512B2 (ja)	2000-11-29	2008-07-30	伊藤ハム株式会社	粉末製剤及びその製造方法
AU2004231342A1 (en)	2003-04-14	2004-11-04	Vectura Ltd	Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
GB0327723D0 (en)	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
GB0525254D0 (en)	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
GB0622818D0 (en)	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds

2003
- 2003-11-14 GB GBGB0326632.7A patent/GB0326632D0/en not_active Ceased
2004
- 2004-11-04 HU HUE04798927A patent/HUE034450T2/en unknown
- 2004-11-04 CN CN200480033194.XA patent/CN1878537B/zh not_active Expired - Lifetime
- 2004-11-04 ES ES04798927.2T patent/ES2645442T3/es not_active Expired - Lifetime
- 2004-11-04 CA CA2542450A patent/CA2542450C/en not_active Expired - Lifetime
- 2004-11-04 EP EP04798927.2A patent/EP1689360B1/en not_active Revoked
- 2004-11-04 EP EP18157741.2A patent/EP3354263B1/en not_active Expired - Lifetime
- 2004-11-04 SI SI200432411T patent/SI1689360T1/sl unknown
- 2004-11-04 ES ES18157741T patent/ES2929899T3/es not_active Expired - Lifetime
- 2004-11-04 PL PL18157741.2T patent/PL3354263T3/pl unknown
- 2004-11-04 FI FIEP18157741.2T patent/FI3354263T3/fi active
- 2004-11-04 EP EP17187255.9A patent/EP3275435A1/en not_active Withdrawn
- 2004-11-04 CN CN201410347450.8A patent/CN104224720A/zh active Pending
- 2004-11-04 JP JP2006538991A patent/JP4991304B2/ja not_active Expired - Lifetime
- 2004-11-04 WO PCT/IB2004/003804 patent/WO2005046636A1/en not_active Ceased
- 2004-11-04 DK DK04798927.2T patent/DK1689360T3/da active
- 2004-11-04 SI SI200432523T patent/SI3354263T1/sl unknown
- 2004-11-04 PL PL04798927T patent/PL1689360T3/pl unknown
- 2004-11-04 AU AU2004288644A patent/AU2004288644B2/en not_active Expired
- 2004-11-04 HU HUE18157741A patent/HUE060507T2/hu unknown
- 2004-11-04 PT PT47989272T patent/PT1689360T/pt unknown
- 2004-11-04 PT PT181577412T patent/PT3354263T/pt unknown
- 2004-11-04 DK DK18157741.2T patent/DK3354263T3/da active
- 2004-11-11 US US10/575,656 patent/US20070071690A1/en not_active Abandoned
2009
- 2009-08-06 US US12/536,980 patent/US20100035854A1/en not_active Abandoned
- 2009-08-06 US US12/536,998 patent/US8211405B2/en not_active Expired - Lifetime
2011
- 2011-10-27 US US13/283,295 patent/US8246935B2/en not_active Expired - Lifetime
2012
- 2012-08-17 US US13/588,655 patent/US8414867B2/en not_active Expired - Fee Related
2015
- 2015-02-26 HK HK15101939.5A patent/HK1201447A1/xx unknown
2017
- 2017-09-15 CY CY20171100978T patent/CY1119350T1/el unknown

Also Published As

Publication number	Publication date
CN1878537B (zh)	2014-08-20
AU2004288644B2 (en)	2011-05-12
EP1689360B1 (en)	2017-08-23
CN1878537A (zh)	2006-12-13
AU2004288644A1 (en)	2005-05-26
US20100035854A1 (en)	2010-02-11
WO2005046636A1 (en)	2005-05-26
GB0326632D0 (en)	2003-12-17
DK1689360T3 (da)	2017-11-13
US20130014758A1 (en)	2013-01-17
CY1119350T1 (el)	2018-02-14
HK1201447A1 (en)	2015-09-04
US20070071690A1 (en)	2007-03-29
EP3354263A1 (en)	2018-08-01
CA2542450A1 (en)	2005-05-26
JP4991304B2 (ja)	2012-08-01
ES2645442T3 (es)	2017-12-05
EP1689360A1 (en)	2006-08-16
SI3354263T1 (sl)	2023-04-28
US8414867B2 (en)	2013-04-09
CA2542450C (en)	2013-08-13
PL3354263T3 (pl)	2023-01-23
US8211405B2 (en)	2012-07-03
FI3354263T3 (fi)	2022-11-30
CN104224720A (zh)	2014-12-24
HUE060507T2 (hu)	2023-03-28
PL1689360T3 (pl)	2017-11-30
SI1689360T1 (sl)	2017-12-29
US20120107406A1 (en)	2012-05-03
US8246935B2 (en)	2012-08-21
HUE034450T2 (en)	2018-02-28
JP2007511502A (ja)	2007-05-10
PT3354263T (pt)	2022-11-11
DK3354263T3 (da)	2022-11-14
ES2929899T3 (es)	2022-12-02
EP3275435A1 (en)	2018-01-31
US20100028269A1 (en)	2010-02-04
EP3354263B1 (en)	2022-08-10

Publication	Publication Date	Title
GB0326632D0 (en)	2003-12-17	Dry powder formulations
IL162642A0 (en)	2005-11-20	Formulations
EP1487524A4 (en)	2011-01-12	INHALER FOR DRY POWDER
IL162858A0 (en)	2005-11-20	Dry powder inhaler
EP1487417A4 (en)	2010-03-17	DRY POWDER DRUG FORMULATIONS
EP1632213A4 (en)	2009-08-26	COSMETIC PREPARATION
IL174735A0 (en)	2006-08-20	Dry powder inhaler
ZA200408247B (en)	2006-03-29	Dry powder inhalant composition
GB0323701D0 (en)	2003-11-12	Formulations
ZA200408245B (en)	2007-03-28	Dry powder compositions
GB0321610D0 (en)	2003-10-15	Dry powder inhaler
ZA200409971B (en)	2006-02-22	Powder formulations.
GB0325383D0 (en)	2003-12-03	Oral formulations
GB0307765D0 (en)	2003-05-07	Tissue-adhesive formulations
GB0218194D0 (en)	2002-09-11	Solid formulations
IL155435A0 (en)	2003-11-23	Solid biocide formulations
GB0310259D0 (en)	2003-06-11	Cosmetic compositions
GB0418117D0 (en)	2004-09-15	Cosmetic compositions
GB0214147D0 (en)	2002-07-31	Formulations
GB0319667D0 (en)	2003-09-24	Dry powder inhaler
GB0319549D0 (en)	2003-09-24	Formulations
GB0319551D0 (en)	2003-09-24	Formulations
GB0318871D0 (en)	2003-09-17	Tissue-adhesive formulations
GB0318503D0 (en)	2003-09-10	Formulations
HK1074384A (en)	2005-11-11	Dry powder compositions